Alkem Laboratories Results Earnings Call for Q2FY24
Conference Call with Alkem Laboratories Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.07-11-2023
07-11-2023
Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Alkem Laboratories Ltd.
Pharmaceuticals company Alkem Laboratories announced Q2FY24 & H1FY24 results: Q2FY24: Total Revenue from Operations was Rs 34,402 million, YoY growth of 11.7% India sales were Rs 23,278 million, YoY growth of 5% International sales were Rs 10,542 million, YoY growth of 27.1% Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) was Rs 7,467 million, resulting in an EBITDA margin of 21.7% vs. 14.7% in Q2FY23. EBITDA increased by 64.5% YoY. R&D; expenses for the quarter were Rs 1,158 million, or 3.4% of total revenue from operations compared to Rs 1,305 million in Q2FY23 at 4.2% of total revenue from operations Profit before tax (PBT) after the exceptional item was Rs 6,480 million, a growth of 61.1% compared to Q2FY23 Exceptional item of Rs 577 million debit was on account of impairment of fixed assets Net Profit (after Minority Interest) was Rs 6,205 million, with YoY growth of 87.6% H1FY24: Total Revenue from Operations was Rs 64,079 million, YoY growth of 13.3% India sales were Rs 42,285 million, YoY growth of 5.8% International sales were Rs 20,688 million, YoY growth of 30.2% Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) was Rs 11,359 million, resulting in an EBITDA margin of 17.7% vs. 11.6% in H1FY23. EBITDA increased by 72.9% YoY R&D; expenses for H1FY24 was Rs 2,360 million, or 3.7% of total revenue from operations compared to Rs 2,625 million in H1FY23 at 4.6% of total revenue from operations Profit before tax (PBT) after the exceptional item was Rs 10,009 million, a growth of 80.6% compared to H1FY23 Exceptional item of Rs 577 million debit was on account of impairment of fixed assets Net Profit (after Minority Interest) was Rs 9,073 million, YoY growth of 97.9% Commenting on the results, Sandeep Singh, Managing Director, Alkem said, " Continuing our trend of improved performance, Q2 builds on the momentum gained in Q1 with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in US market and increased operating leverage, resulting in improved EBITDA margins. Domestic growth for the quarter remained subdued due to sporadic monsoon. However, we observed significant traction in the domestic market during the month of September and anticipate continued momentum in the coming quarter. Our international business, both US and Non-US market maintains its robust performance, which was evident in Q1 and continues to flourish. Our biosimilars portfolio is performing impressively, with Enzene’s latest product addition (Ranibizumab), taking the product suite to 7, and witnessing significant traction in the domestic biosimilars market. We are committed to carrying forward the momentum of better operational performance, building on our recent successes." Result PDF07-11-2023
Alkem Laboratories Ltd - 539523 - Closure of Trading Window
The Financial Results for quarter and half year ended 30th Sept having been communicated to the Stock Exchange today 7th Nov 23 the trading window shall open on 10th Nov, 23.07-11-2023
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed press release and analyst presentation on Q2FY24 earnings and business updates and the same shall be uploaded on website of the Company07-11-2023
Alkem Laboratories Ltd - 539523 - Announcement Under Regulation 30 (LODR)- Cut-Off Date For Postal Ballot
The BOD have approved the amendment to the objects of MOA in its meeting held today.07-11-2023
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
The BoD at its meeting today approved the amendment to the object clause of MOA by inserting certain new object clauses after sub clause 2 in clause III(A) - Main objects for widening the scope of activities to be carried out by the Company under ambit of healthcare business, subject to approval of shareholders by way of Postal Ballot07-11-2023
Alkem Laboratories Ltd - 539523 - Results- Financial Results For Quarter Ended September 30, 2023
Please find attached herewith copy of unaudited financial results and limited review of the Statutory Auditors is enclosed herewith07-11-2023
Alkem Laboratories Ltd - 539523 - Board Meeting Outcome for Outcome Of Board Meeting Dated 07/11/2023
The Board of Directors at its meeting held today i.e. 07th November, 2023, has, inter alia: 1. approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2023. 2. approved the amendment to object clause of the Memorandum of Association of the Company by inserting certain new object clauses after sub clause 2 of Clause III(A) - Main Objects ('The objects to be pursued by the Company on its incorporation'), subject to approval of shareholders of the Company through Postal Ballot. Accordingly, we are enclosing herewith Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2023. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 1.40 p.m.07-11-2023
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 attached herewith is the details of Analyst/ Institutional Investor meeting to be conducted at Centrum Virtual conference 'Orion 2023 - Changing India to Prosperous Bharat'.03-11-2023